SJS Investment Consulting’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17K Buy
1,696
+1,441
+565% +$13.3K ﹤0.01% 1074
2026
Q2
$2.14K Buy
255
+211
+480% +$1.92K ﹤0.01% 1751
2026
Q1
$397 Buy
44
+32
+267% +$505 ﹤0.01% 1820
2025
Q4
$219 Hold
12
– – ﹤0.01% 1781
2025
Q3
$176 Hold
12
– – ﹤0.01% 1489
2025
Q2
$219 Sell
12
-59
-83% -$1.2K ﹤0.01% 1352
2025
Q1
$1.41K Hold
71
– – ﹤0.01% 868
2024
Q4
$1.22K Buy
71
+43
+154% +$809 ﹤0.01% 928
2024
Q3
$560 Buy
+28
New +$435 ﹤0.01% 1289

Other funds holding ADMA

SJS Investment Consulting's ADMA Position: Q3 2026 in Review

SJS Investment Consulting increased its ADMA Biologics (ADMA) stake by 565% in Q3 2026, buying an estimated $13.3K and bringing the position to 1,696 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #1074.

SJS Investment Consulting first reported a position in ADMA in Q3 2024 and has held it in 9 quarters since. 329 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • SJS Investment Consulting held 1,696 shares of ADMA Biologics worth $17K as of Q3 2026.
  • SJS Investment Consulting bought 1,441 ADMA Biologics shares in Q3 2026, an estimated $13.3K.
  • ADMA Biologics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #1074 holding.
  • SJS Investment Consulting first reported a position in ADMA Biologics in Q3 2024 and has held it in 9 quarters since.
  • 329 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.